Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.
Vanella V, Festino L, Vitale MG, Alfano B, Ascierto PA. Vanella V, et al. Among authors: vitale mg. Expert Opin Emerg Drugs. 2021 Jun;26(2):79-92. doi: 10.1080/14728214.2021.1901884. Epub 2021 Mar 19. Expert Opin Emerg Drugs. 2021. PMID: 33686894 Review.
Atezolizumab for the treatment of breast cancer.
Basile D, Pelizzari G, Vitale MG, Lisanti C, Cinausero M, Iacono D, Puglisi F. Basile D, et al. Among authors: vitale mg. Expert Opin Biol Ther. 2018 May;18(5):595-603. doi: 10.1080/14712598.2018.1469619. Epub 2018 May 8. Expert Opin Biol Ther. 2018. PMID: 29690797 Review.
Nivolumab for the treatment of small cell lung cancer.
Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Curvietto M, Ascierto PA. Simeone E, et al. Among authors: vitale mg. Expert Rev Respir Med. 2020 Jan;14(1):5-13. doi: 10.1080/17476348.2020.1681977. Epub 2019 Oct 29. Expert Rev Respir Med. 2020. PMID: 31622114 Review.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA. Cortellini A, et al. Among authors: vitale mg. J Transl Med. 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x. J Transl Med. 2019. PMID: 31730009 Free PMC article.
Melanoma immunotherapy: strategies to overcome pharmacological resistance.
Trojaniello C, Vitale MG, Scarpato L, Esposito A, Ascierto PA. Trojaniello C, et al. Among authors: vitale mg. Expert Rev Anticancer Ther. 2020 Apr;20(4):289-304. doi: 10.1080/14737140.2020.1745634. Epub 2020 Apr 6. Expert Rev Anticancer Ther. 2020. PMID: 32195606
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Montesarchio V, Parrela R, Iommelli C, Bianco A, Manzillo E, Fraganza F, Palumbo C, Rea G, Murino P, De Rosa R, Atripaldi L, D'Abbraccio M, Curvietto M, Mallardo D, Celentano E, Grimaldi AM, Palla M, Trojaniello C, Vitale MG, Million-Weaver SL, Ascierto PA. Montesarchio V, et al. Among authors: vitale mg. J Immunother Cancer. 2020 Aug;8(2):e001089. doi: 10.1136/jitc-2020-001089. J Immunother Cancer. 2020. PMID: 32784217 Free PMC article.
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival.
Mannavola F, Mandala M, Todisco A, Sileni VC, Palla M, Minisini AM, Pala L, Morgese F, Di Guardo L, Stucci LS, Guida M, Indini A, Quaglino P, Ferraresi V, Marconcini R, Tronconi MC, Rossi E, Nigro O, Occelli M, Cortellini A, Quadrini S, Palmieri G, Pigozzo J, Ascierto PA, Vitale MG, Strippoli S, Ferrucci PF, Berardi R, Randon G, Cardone P, Schinzari G, Silvestris F, Tucci M. Mannavola F, et al. Among authors: vitale mg. Front Oncol. 2020 Sep 15;10:1652. doi: 10.3389/fonc.2020.01652. eCollection 2020. Front Oncol. 2020. PMID: 33042809 Free PMC article.
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Ottaviano M, et al. Among authors: vitale mg. J Immunother Cancer. 2020 Oct;8(2):e001154. doi: 10.1136/jitc-2020-001154. J Immunother Cancer. 2020. PMID: 33060148 Free PMC article.
307 results